Article (Scientific journals)
Pretreatment with P2Y12 inhibitors and outcome in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention
Gach, Olivier; Nyssen, Anne-Sophie; GAYETOT, Christiane et al.
2018In Journal of Cardiovascular Medicine, 19 (5), p. 234-239
Peer Reviewed verified by ORBi
 

Files


Full Text
gach2018.pdf
Publisher postprint (126.25 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Acute coronary syndrome; Outcome; P2Y12 inhibitors; STsegment elevation myocardial infarction
Abstract :
[en] Aims Preload with clopidogrel, ticagrelor, or prasugrel in the setting of ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) is frequently applied. Limited data are available regarding the outcome impact of pretreatment with these drugs in the real world. Methods and results The outcome of 760 STEMI patients treated by primary PCI receiving clopidogrel, prasugrel, or ticagrelor (nU269, 327, 164, respectively) was evaluated. Patients in the clopidogrel group were older, whereas those in the ticagrelor group had less hypertension but were more active smokers. Angiographic characteristics were comparable among the three groups. At 1 month, more events were observed in the clopidogrel group (11.1%) than in the ticagrelor and prasugrel groups (7.1 vs. 5.1%, P=0.025), whereas the number of events in the ticagrelor and prasugrel groups did not differ. At 1 year, similar differences existed, mainly driven by a higher rate of death (19.5%, P=0.008) or stent thrombosis (2 vs. 1.3% for ticagrelor, P=0.132; vs. 0.3% for prasugrel, P=0.07) in the clopidogrel group. In-hospital and 1-year bleeding rates were similar between groups. Conclusion In real-world practice, pretreatment with prasugrel or ticagrelor in ongoing STEMI treated by primary PCI seems to be a well tolerated alternative strategy compared with clopidogrel but provides superior benefit in terms of outcomes. © 2018 Italian Federation of Cardiology. All rights reserved.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Gach, Olivier ;  Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Nyssen, Anne-Sophie ;  Université de Liège - ULiège > Département de Psychologie > Ergonomie et intervention au travail
GAYETOT, Christiane ;  Centre Hospitalier Universitaire de Liège - CHU > Service de psychiatrie
Magne, J.;  Centre Hospitalier Universitaire de Limoges, Service de Cardiologie, Limoges, France
Oury, Cécile  ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : GIGA - Cardiovascular Sciences
Lancellotti, Patrizio  ;  Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation
Language :
English
Title :
Pretreatment with P2Y12 inhibitors and outcome in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention
Publication date :
2018
Journal title :
Journal of Cardiovascular Medicine
ISSN :
1558-2027
eISSN :
1558-2035
Publisher :
Lippincott Williams and Wilkins
Volume :
19
Issue :
5
Pages :
234-239
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 21 June 2018

Statistics


Number of views
101 (7 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
2
Scopus citations®
without self-citations
2
OpenCitations
 
2

Bibliography


Similar publications



Contact ORBi